Nature: He Dayi's team found that Eli Lilly's newly approved monoclonal antibody is effective against various subtypes of Omicron

On March 3, 2022, the team of He Dayi from Columbia University published a research paper entitled: Antibody evasion properties of SARS-CoV-2 Omicron sublineages
in Nature .

In laboratory experiments using 19 monoclonal antibodies, the research team found that only the recently approved bebtelovimab monoclonal antibody neutralized all three isoforms of Omicron
.

bebtelovimab was developed by Eli Lilly and received an Emergency Use Authorization (EUA) from the U.
S.
FDA on February 11, 2022 for the treatment of mild to moderate mild to moderate disease in adults and pediatric patients 12 years of age and older (at least 40 kg).
Patients with COVID-19, and those at high risk of developing severe COVID-19
.

After the confirmation of the Omicron BA.
1 mutant, continued monitoring has revealed two further mutated clades: BA.
1 and BA.
2 with the R346K mutation
.

He Dayi et al.
investigated the susceptibility of Omicron subtypes to neutralizing sera from individuals previously infected with wild-type new coronavirus (10 people), vaccinated with Pfizer-BioNTech (13 people) or Individuals with the Moderna vaccine (12 people), and those who received any of the above mRNA vaccines as a booster (15 people)
.

The research team concluded: The emergence of variants has led to fewer treatment options, and we must continue to develop new strategies to control the new coronavirus
.

About He Dayi

When it comes to He Dayi, we have to mention his greatest contribution - cocktail therapy.
The application of cocktail therapy has made AIDS a chronic disease, and millions of AIDS patients have survived
.

He Dayi was born on November 3, 1952 in Taiwan, China, and immigrated to Los Angeles, California, USA with his family when he was 12 years old
.

In 1970, He Dayi was admitted to the Massachusetts Institute of Technology, and graduated with honors four years later, and later received a doctorate in medicine from Harvard University
.

On June 5, 1981, the U.
S.
Centers for Disease Control and Prevention released a report of five AIDS cases, the first time AIDS was discovered in the world
.

Since then, He Dayi has devoted himself to AIDS research, becoming one of the first scientists in the world to realize that AIDS is caused by a virus, and one of the first scientists to elucidate the replication diversity of HIV
.

In 1996, in the face of the frequent drug resistance problems of AIDS patients, He Dayi proposed a "cocktail therapy", which combined a variety of anti-AIDS drugs into a combination of protease inhibitor drugs, nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors.
The combination of non-nucleoside reverse transcriptase inhibitor drugs can be more effective in the treatment of AIDS than single drugs, and it is less likely to develop drug resistance
.

Since its use in 1996, cocktail therapy has effectively reduced the mortality rate of AIDS patients, and it is still one of the most commonly used and most effective AIDS treatment methods
.

Due to the outstanding contribution of "cocktail therapy" to AIDS treatment, He Dayi was selected as the person of the year by the US "Time" magazine in 1996, and in 2010, he was called "the person who defeated AIDS" by "Time" magazine
.

Since then, He Dayi has devoted himself to the prevention and treatment of AIDS and other viral diseases, and has achieved a series of important research results
.

On March 8, 2021, He Dayi's team published a research paper entitled: Antibody Resistance of SARS-CoV-2 Variants B.
1.
351 and B.
1.
1.
7 in Nature
.

The study shows that the new crown Alpha mutant strain (B.
1.
1.
7) and Beta mutant strain (B.
1.
351) can escape a variety of monoclonal antibodies targeting the N-terminal domain (NTD) of the new coronavirus S protein, as well as targeting the receptor Monoclonal antibody to the body binding domain (RBD)
.

Original source:

Iketani, S.